Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting

Rhea-AI Summary

Atreca, a clinical-stage biotechnology company (NASDAQ: BCEL), announced it will present data from the Phase 1b study of ATRC-101 at the American Society of Clinical Oncology 2023 Annual Meeting from June 2-6 in Chicago. The presentation, titled "Interim update of the ATRC-101 phase 1b trial in advanced solid tumors", will take place on June 4, 2023, from 9:45 AM to 12:45 PM CDT. This trial aims to evaluate ATRC-101's effectiveness in treating multiple solid tumors, expanding Atreca's innovative antibody-based therapeutic portfolio that targets unique tumor antigens derived from the human immune response. The company is actively enrolling patients for this trial, highlighting its commitment to advancing cancer therapies.

Positive

• Presentation scheduled for June 4, 2023, showcasing progress in ATRC-101 development.
• Ongoing enrollment in Phase 1b trial indicates commitment to advancing cancer therapeutics.

Negative

• None.

SAN CARLOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that data from the Phase 1b study of ATRC-101 will be presented during an oral abstract session at the American Society of Clinical Oncology 2023 Annual Meeting, being held June 2-6, 2023 in Chicago, Illinois.

Details of the presentation are as follows:

Abstract Title: Interim update of the ATRC-101 phase 1b trial in advanced solid tumors.
Abstract Number: 2505
Session: Developmental Therapeutics - Immunotherapy
Date / Time: June 4, 2023; 9:45am – 12:45pm CDT
Presenting Author: Dr. Bartosz Chmielowski, Health Sciences Clinical Professor of Medicine, Division of Hematology-Oncology, University of California Los Angeles

About Atreca, Inc.
Atreca is a biopharmaceutical company developing novel antibody-based therapeutics generated by its differentiated discovery platform. Atreca's platform allows access to an unexplored landscape in oncology through the identification of unique antibody-target pairs generated by the human immune system during an active immune response against tumors. These antibodies provide the basis for first-in-class therapeutic candidates, such as our lead product candidate ATRC-101. A Phase 1b study evaluating ATRC-101 in multiple solid tumor cancers is currently enrolling patients. For more information on Atreca, please visit www.atreca.com.

Forward-Looking Statements
This release contains statements regarding matters that are not historical facts that are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements regarding our strategy and future plans, including statements regarding the development of ATRC-101, and our preclinical and clinical plans and the timing thereof. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the initiation, timing, progress and results of our research and development programs, preclinical studies, clinical trials, regulatory submissions, and other matters that are described in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) and available on the SEC's website at www.sec.gov, including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law.

Contacts

Atreca, Inc.
Herb Cross
Chief Financial Officer
info@atreca.com

Investors:
Alex Gray, 650-779-9251
agray@atreca.com

Media:
Julia Fuller, 858-692-2001
Julia@fordhutmanmedia.com

FAQ

What is the purpose of the ATRC-101 Phase 1b trial?

The ATRC-101 Phase 1b trial aims to evaluate the drug's effectiveness in treating multiple solid tumor cancers.

When will data from the ATRC-101 trial be presented?

Data from the ATRC-101 trial will be presented on June 4, 2023, at the American Society of Clinical Oncology Annual Meeting.

Who is presenting the data on ATRC-101?

Dr. Bartosz Chmielowski, Health Sciences Clinical Professor of Medicine at UCLA, will present the data.

What is Atreca's focus as a biotechnology company?

Atreca focuses on developing novel antibody-based therapeutics through its unique discovery platform based on the human immune response.

What is the significance of the ASCO meeting for Atreca?

The ASCO meeting provides a platform for Atreca to share interim results of its clinical trials, potentially influencing investor and market interest.